Adobe 
Sitecore 
Gradial 
PEGA 
AI Adoption Is Accelerating, But Where Is the Oversight?
A governance workshop to keep your data safe.
Your commercial and medical affairs teams are already using AI assistants every day. Does your legal and compliance team know which ones, or what those tools touch? Join CI's Claudia Beqaj and Classie AI co-founder Dr. Lawrence Spracklen for a live conversation on the real risks life sciences companies face right now: PHI exposure, rare disease de-identification, and audit trails that hold up under scrutiny.
Hosted by Claudia Beqaj
HLS Practice Lead, CI
Hosted by Dr. Lawrence Spracklen
Chief Science Officer, Classie AI
Webinar Starts In
Real controls for real agents, not just a policy document
A governance workshop to keep your data safe. This session covers where AI oversight is falling behind in life sciences today, with real answers on PHI, rare disease data, and proof that holds up under audit.
Whether your commercial and medical affairs teams using AI tools is a data risk or a compliance risk
What "your data never leaves our environment" actually means in practice
How rare disease programs handle re-identification risk at small patient counts
How to build an audit trail that holds up under regulatory scrutiny
Claudia Beqaj
HLS Practice Lead, CI
25 years in pharma, including roles at Pfizer, Merck, and Boehringer Ingelheim. Opens and hosts the session, joined by Classie AI co-founder Dr. Lawrence Spracklen as technical speaker.
Dr. Lawrence Spracklen
Chief Science Officer, Classie AI
Built AI systems for the enterprise for over a decade, most recently as Chief Science Officer at Arkifi through its acquisition by S&P Global. Now co-leads Classie AI's work giving organizations real-time control over their AI agents.
Join Us
Thursday
September 24th
2:00 PM EDT
Follow us
